BDNF and hearing loss disorder: Our results pave the way for additional development of BDNF and M3, including an assessment of biostability, bioavailability and efficacy in animal models with damaged SGN type 1 afferents and synapses, to further establish their potential to treat hidden hearing loss and other clinical paradigms that would benefit from restoring these synapses.